Medical network - March 15 medical insurance directory after 8 years to update, trillions of medical market stir up again! Diabetes drug market as part of the giants in China's pharmaceutical market, this is medical insurance directory changes to its far-reaching influence. Diabetes drug b class a, new indications, cancel restrictions... All of these become enterprise's ambitious new opportunity in the future. For many years to nearly 40 billion, led by acarbose oral medicines market, under the refactoring, "cake" how to?
Was lit, DPP 4 inhibitors increase the most
Overview the new medical insurance directory adjust some of the diabetes drug use situation, western medicine diabetes drug use the most number of new varieties, increase rate is as high as 79%, much more careful classification of insulin.
Classification of insulin adjustment, the class changes of insulin and insulin analogs, according to the short-term and long-term effect, premix, divided into four types, and each type of classification.
A class of new drugs, the biggest growth is the DPP 4 inhibitors, agger column dean, Glenn dean, Glenn dean sand, d Glenn dean, west Glenn, also other new mig calcium alcohol and mig columns nai, gliclazide Ⅱ.
Recombinant human insulin (a short-acting, premixed) and acarbose, Glenn urea changed from class b to class a variety.
Pioglitazone, rosiglitazone cancellation indications.
"Cake" large - nearly 40 billion diabetes drug market
The world health organization in 2016, according to a report issued by the number of people with diabetes for more than 400 million people worldwide, most live in developing countries, China's diabetes rates "explosive" growth. So size large patient group, is China's huge diabetes drug market.
, according to senior m Intranet database public medical institutions in 2015 China (city public hospitals, public hospitals at the county level, the community of cities and towns and townships four terminal) diabetes medication combined sales of 37.3 billion yuan.
Figure 1: the public medical institutions in recent years, diabetes medication China sales (unit: one hundred million yuan)
Along with our country continue to increase the number of diabetes, diabetes drug market will continue to expand in the future. The new diabetes drugs in medical insurance directory of adjustment, is bound to the pattern of the diabetes drug market brings huge changes.
Eight new recruit into the b - foreign drug firms to dominate
In diabetes medicine new medicine, eight (agger column, Glenn, the sand Glenn dean, statins d Glenn dean, west Glenn dean, mig column alcohol, calcium mig column nai, gliclazide Ⅱ) are all health b, six of them corresponding with approval for foreign companies, and four for exclusive. Thus, domestic market is still dominated by foreign drug companies oral medications.
Table 1: the new medical insurance directory diabetes drugs new varieties
Past performance is uneven, the new power market
Eight new drugs in the domestic market is mixed. , according to m Intranet database gliclazide (including gliclazide Ⅰ and Ⅱ) for nearly three years in the domestic sales is the most bright eye, 2015 urban public medical institutions in China (China's urban public hospitals, public hospitals, community health center, the county level in towns and townships) terminal sales as high as 1.11 billion yuan, Glenn dean, mig column alcohol, followed by sales are more than one hundred million yuan.
Figure 2: new drug (part) in recent years, public medical institutions in China sales (unit: ten thousand yuan)
New DPP 4 inhibitors into the medical insurance directory will promote the upgrading of domestic diabetes drug treatment products, followed by a the foreign drug companies will also secondary impact diabetes market as a whole.
B class rise a class - the second outbreak in sight
Adjustment of the new medical insurance directory of diabetes drugs, in addition to the new quantity high-profile, b class a rise of the varieties of the same concern. Contrast 2009 medicare catalog, 2009 medical insurance directory of recombinant human insulin, acarbose, Glenn beauty urea from class b to class a. Predictably, these drugs in the field of corresponding market share will have obvious ascension.
Recombinant human insulin
Insulin resistance in diabetes drugs in the market to occupy the half. The rapid development of the diabetes market for insulin domestic enterprises has brought unprecedented opportunities, as one of the main varieties of recombinant human insulin made an important contribution.
Domestic production of recombinant human insulin is not much, tonghua dongbao pharmaceutical industry is one of the leader. According to tonghua dongbao half annual report data in 2016, the first half of 2016 to achieve revenue 89045.97 ten thousand yuan, a year-on-year growth of 14.12% over the same, including: recombinant human insulin achieve revenue 72876.82 ten thousand yuan, accounting for 81.84% of the proportion of revenue.
The medical insurance directory, recombinant human insulin from class b to class a, in domestic has the drug production approval of the drug companies is undoubtedly a major positive.
acarbose
Acarbose is leading varieties of diabetes oral drugs. Main reduce postprandial hyperglycemia, acarbose in carbohydrates as staple food effect is particularly evident in the patient group, so their consecutive years ranked first in the domestic market of diabetes drugs.
Figure 2: acarbose in recent years, public medical institutions in China sales (unit: ten thousand yuan)
According to the meters, according to data from the network acarbose urban public medical institutions in China from 2013 to 2015 has been a steady rise in sales, as high as 5.84 billion yuan in 2015; At the same time, acarbose in retail terminal sales also prominent, the city of retail pharmacies in China in 2015 sales are more than 1.25 billion yuan. By the above data accumulated, acarbose in the Chinese market sales of more than 7 billion yuan, is worthy of medicines popular king.
In addition, according to m, according to data from the network of acarbose in the domestic market dominant position occupied by a foreign drug companies bayer, but nearly three years domestic drug firms hangzhou sino-us east China pharmaceutical market share is rising year by year.
Figure 3: acarbose city brand pattern of medical institutions in China in 2015
Glenn beauty urea
Sulfonylurea medications as insulin secretion accelerant, its mechanism is the direct effects on islet beta sulfonylurea receptor on the cell membrane, promote insulin secretion, strengthen dine high blood sugar to insulin release after excitation. Glenn beauty urea as the second generation of sulfonylurea antidiabetic drug, is also a sulfonylurea medications in the best-selling products in China.
Figure 4: Craig beauty urea public medical institutions in China in recent years the sales (unit: ten thousand yuan)
According to m Intranet data, Glenn urea urban public medical institutions in China from 2013 to 2015 also showed a trend of steady growth in sales, in 2015 to 2015 yuan, public medical institutions in our country oral medications ranked fourth in the market.
At home, Glenn beauty urea market share is still occupied by a giant sanofi firmly, and domestic drug firms is shiyao European pharmaceutical co., jiangsu wanbang biochemical medicine, shandong xinhua pharmaceutical followed suit.
Figure 5: Craig beauty urea city brand pattern of medical institutions in China in 2015
Two hands control - the market reconstruction to be seen
In people look to focus on the new health care at the same time, the new quantity and variety in the catalogue may be more should pay attention to the meaning behind the changes. Industry it is thought that medical insurance directory to adjust the ground is just beginning, later will introduce multiple industrial policy and the synergy of form a complete set, especially the new health care is important to function as a standard of payment.
Adjustment of 2017 drug directory fully embodies the "fill a vacancy, selection, support innovation, encourage competition," the policy thinking, for children, innovative medicines, major disease treatment medicine and national medicine to consider and support. As one of the major diseases, diabetes because of new drug quantity and dramatic, at the same time, their health will come out in the subsequent negotiations directory and health insurance payment standard, it is also worth focusing on.
So far, have been reported in fujian province pharmaceutical joint limit sunlight procurement directory (first batch) and health care the highest selling price and payment settlement price. Which states that diabetes medication as special patient groups use to receive government preferential treatment - without competitive products and comparison, the medical insurance payment settlement price calculated on the basis of the highest retail price of 8 fold.
Thus, health insurance directory and medicare payment standard is about the future of medical market two hands. Under the dual control, market refactoring still need to wait until after the supporting policies to carry out the outcome.
conclusion
Risk factors by unhealthy diet and lack of exercise, the influence of the number of diabetes in our country have been showing a tendency of growing larger in recent years, diabetes drug market scale has been expanded. The new medical insurance directory on diabetes medication adjustment, will make the corresponding market share and product price of the drug produce different changes, diabetes medication in expanding market scale at the same time, the change of market pattern deserves more attention in the future. |
